Contribute Try STAT+ Today

Good morning. Elizabeth Cooney here in Boston filling in for Ed Silverman on a balmy August morning. Lots to catch up on today:

The Trump administration on Wednesday finalized long-sought rules for when Medicare will cover CAR-T treatments, often curative therapies that harness patients’ own immune cells against their cancer, STAT reports. Medicare will pay for CAR-T therapies even when used to treat conditions that aren’t FDA-approved. The two approved CAR-T treatments on the market are Yescarta from Gilead Sciences for non-Hodgkin lymphoma and Kymriah from Novartis for acute lymphoblastic leukemia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.